MARKET

NURO

NURO

Neurometrix Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.860
+0.220
+6.04%
Closed 16:38 07/05 EDT
OPEN
3.490
PREV CLOSE
3.640
HIGH
3.890
LOW
3.450
VOLUME
41.36K
TURNOVER
--
52 WEEK HIGH
38.75
52 WEEK LOW
2.700
MARKET CAP
27.52M
P/E (TTM)
-7.2028
1D
5D
1M
3M
1Y
5Y
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers
Benzinga · 06/21 21:45
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year.
Benzinga · 05/23 07:57
NNVC, BEST and PYR among mid-day movers
Gainers: Leju Holdings Limited (LEJU) +47%. Redbox Entertainment (RDBX) +33%. SIGA Technologies (SIGA) +26%. Getnet (GET) +25%. Allarity (ALLR) +23%. NanoViricides (NNVC) +22%. Processa Pharmaceuticals (PCSA) +22%. TherapeuticsMD (TXMD) +17%.
Seekingalpha · 05/20 16:37
Short Volatility Alert: NeuroMetrix
On Thursday, shares of NeuroMetrix, Inc. (NASDAQ: NURO) experienced volatile short activity. After the activity, the stock price went up +76.28% to $5.50.  The overall sentiment for NURO has been Neutral.
Benzinga · 05/20 15:05
Immix Biopharma, MDxHealth top healthcare gainers; Evofem, Bright Green lead losers' pack
Gainers: Immix Biopharma (IMMX) +48%. MDxHealth (MDXH) +31%. ClearPoint Neuro (CLPT) +16%. Covetrus (CVET) +14%. Kronos Bio (KRON) +13%. Losers: Evofem Biosciences (EVFM) -58%. Bright Green (BGXX) -26%. Foghorn Therapeutics (FHTX) -19%. NeuroMetrix (NURO) ...
Seekingalpha · 05/20 14:07
20 Stocks Moving in Friday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share.
Benzinga · 05/20 10:19
Why Is NeuroMetrix (NURO) Stock Up 70% Today?
Investor Place · 05/19 18:39
Mid-Afternoon Market Update: Dow Falls 150 Points; NeuroMetrix Shares Spike Higher
U.S. stocks traded mixed toward the end of trading, with the Dow Jones dropping around 150 points on Thursday.
Benzinga · 05/19 18:36
More
No Data
Learn about the latest financial forecast of NURO. Analyze the recent business situations of Neurometrix Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average NURO stock price target is 50.00 with a high estimate of 50.00 and a low estimate of 50.00.
High50.00
Average50.00
Low50.00
Current 3.860
EPS
Actual
Estimate
-0.12-0.09-0.06-0.03
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 28
Institutional Holdings: 583.43K
% Owned: 8.18%
Shares Outstanding: 7.13M
TypeInstitutionsShares
Increased
4
40.48K
New
3
19.51K
Decreased
5
128.59K
Sold Out
5
62.65K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
-0.16%
Healthcare Equipment & Supplies
-0.07%
Key Executives
Chairman/Chief Executive Officer/President/Secretary/Director
Shai Gozani
Chief Financial Officer/Senior Vice President/Treasurer
Thomas Higgins
Independent Director
Bradley Fluegel
Independent Director
David Goodman
Independent Director
Nancy Katz
Independent Director
David Van Avermaete
No Data
No Data
About NURO
NeuroMetrix, Inc. develops and commercializes health care products that utilize non-invasive neurostimulation. The Company is engaged in the designing, building and marketing of medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. It has two principal product categories, which includes point-of-care neuropathy diagnostic tests and wearable neurostimulation devices. Its products include DPNCheck, Quell and ADVANCE System. DPNCheck is a quantitative nerve conduction test that is used to evaluate peripheral neuropathies, such as Diabetic peripheral neuropathy (DPN). Quell a wearable device for symptomatic relief and management of chronic pain. ADVANCE System is a platform for the performance of nerve conduction studies. DPNCheck customers include managed care organizations, endocrinologists, podiatrists and primary care physicians. ADVANCE System customers include occupational health, primary care, internal medicine and many others.

Webull offers kinds of Neurometrix Inc stock information, including NASDAQ:NURO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NURO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NURO stock methods without spending real money on the virtual paper trading platform.